title: Modeling pre-existing immunity to adenovirus in rodents: immunological requirements for successful development of a recombinant adenovirus serotype 5-based ebola vaccine.
abstract: Pre-existing immunity (PEI) to human adenovirus serotype 5 (Ad5) worldwide is the primary limitation to routine clinical use of Ad5-based vectors in immunization platforms. Using systemic and mucosal PEI induction models in rodents (mice and guinea pigs), we assessed the influence of PEI on the type of adaptive immune response elicited by an Ad5-based vaccine for Ebola with respect to immunization route. Splenocytes isolated from vaccinated animals revealed that immunization by the same route in which PEI was induced significantly compromised Ebola Zaire glycoprotein (ZGP)-specific IFN-γ+ CD8+ T cells and ZGP-specific multifunctional CD8+ T cell populations. ZGP-specific IgG1 antibody levels were also significantly reduced and a sharp increase in serum anti-Ad5 neutralizing antibody (NAB) titers were noted following immunization. These immune parameters correlated with poor survival after lethal challenge with rodent-adapted Ebola Zaire virus (ZEBOV). Although the number of IFN-γ+ CD8+ T cells was reduced in animals given the vaccine by a different route from that used for PEI induction, the multifunctional CD8+ T cell response was not compromised. Survival rates in these groups were higher than when PEI was induced by the same route as immunization. These results suggest that antigen-specific multifunctional CD8(+) T cell and Th2 type antibody responses compromised by PEI to Ad5 are required for protection from Ebola. They also illustrate that methods for induction of PEI used in preclinical studies must be carefully evaluated for successful development of novel Ad5-based vaccines.
authors.affiliation: Division of Pharmaceutics, College of Pharmacy, The University of Texas at Austin , Austin, Texas 78712, United States.
authors.forename: Jin Huk
authors.initials: JH
authors.lastname: Choi
authors.forename: Stephen C
authors.initials: SC
authors.lastname: Schafer
authors.forename: Lihong
authors.initials: L
authors.lastname: Zhang
authors.forename: Terry
authors.initials: T
authors.lastname: Juelich
authors.forename: Alexander N
authors.initials: AN
authors.lastname: Freiberg
authors.forename: Maria A
authors.initials: MA
authors.lastname: Croyle
mesh_terms: D000256:Adenoviridae / Q000276:immunology*; D000818:Animals; D000917:Antibody Formation / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D046129:Ebola Vaccines / Q000276:immunology*; D029043:Ebolavirus / Q000276:immunology; D006168:Guinea Pigs; D008297:Male; D051379:Mice; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D046129:Ebola Vaccines
references.citation: Vaccine. 2010 Jan 22;28(4):950-7
references.pmid: 19925902
references.citation: J Immunol. 1995 Sep 1;155(5):2564-70
references.pmid: 7650386
references.citation: Curr Opin Virol. 2012 Jun;2(3):324-9
references.pmid: 22560007
references.citation: PLoS One. 2012;7(1):e30302
references.pmid: 22276174
references.citation: Hum Gene Ther. 2013 Jan;24(1):58-66
references.pmid: 23140508
references.citation: Virology. 2006 Mar 15;346(2):394-401
references.pmid: 16356525
references.citation: J Med Virol. 2012 Sep;84(9):1408-14
references.pmid: 22825819
references.citation: J Cell Biochem. 2009 Nov 1;108(4):778-90
references.pmid: 19711370
references.citation: J Gene Med. 2010 Oct;12(10):840-7
references.pmid: 20963806
references.citation: PLoS One. 2009;4(4):e5308
references.pmid: 19390586
references.citation: Semin Respir Crit Care Med. 2011 Aug;32(4):494-511
references.pmid: 21858752
references.citation: Vaccine. 1999 Aug 6;17(23-24):2991-8
references.pmid: 10462234
references.citation: Mol Ther. 2001 May;3(5 Pt 1):697-707
references.pmid: 11356075
references.citation: J Virol. 2007 May;81(9):4654-63
references.pmid: 17329340
references.citation: J Virol. 2011 May;85(9):4222-33
references.pmid: 21325402
references.citation: Sci Transl Med. 2012 Jan 4;4(115):115ra1
references.pmid: 22218690
references.citation: Nature. 2000 Nov 30;408(6812):605-9
references.pmid: 11117750
references.citation: Trends Mol Med. 2012 Jul;18(7):365-76
references.pmid: 22633438
references.citation: J Infect Dis. 2011 Nov;204 Suppl 3:S1075-81
references.pmid: 21987744
references.citation: Microbiology (Reading). 2013 Jan;159(Pt 1):1-11
references.pmid: 23175507
references.citation: Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7257-61
references.pmid: 7638177
references.citation: Cytokine. 2011 Apr;54(1):1-5
references.pmid: 21239178
references.citation: Curr Gene Ther. 2012 Oct;12(5):362-73
references.pmid: 22845888
references.citation: Ther Deliv. 2011 Oct;2(10):1351-68
references.pmid: 22826888
references.citation: Front Immunol. 2011 Sep 06;2:40
references.pmid: 22566830
references.citation: Annu Rev Pathol. 2013 Jan 24;8:411-40
references.pmid: 23121052
references.citation: Nature. 2006 Jun 15;441(7095):890-3
references.pmid: 16778891
references.citation: J Infect Dis. 2007 Nov 15;196 Suppl 2:S413-20
references.pmid: 17940978
references.citation: Curr Top Microbiol Immunol. 2012;354:1-18
references.pmid: 21053117
references.citation: J Infect Dis. 1999 Feb;179 Suppl 1:S188-91
references.pmid: 9988183
references.citation: Nat Rev Immunol. 2008 Apr;8(4):247-58
references.pmid: 18323851
references.citation: Vaccine. 2012 Jan 5;30(2):142-54
references.pmid: 22085556
references.citation: Adv Exp Med Biol. 2012;750:133-44
references.pmid: 22903671
references.citation: Immunity. 1994 Aug;1(5):433-42
references.pmid: 7533647
references.citation: Vaccine. 2012 Jul 27;30(35):5191-8
references.pmid: 22683663
references.citation: Sci Rep. 2012;2:811
references.pmid: 23155478
references.citation: Clin Vaccine Immunol. 2013 Jan;20(1):1-8
references.pmid: 23100479
references.citation: Expert Opin Biol Ther. 2012 Jul;12(7):859-72
references.pmid: 22559078
references.citation: Mol Pharm. 2011 Feb 7;8(1):3-11
references.pmid: 21047139
references.citation: PLoS One. 2010 Dec 16;5(12):e15301
references.pmid: 21179494
references.citation: J Infect Dis. 2011 Nov;204 Suppl 3:S1053-9
references.pmid: 21987741
references.citation: Virus Res. 2011 Dec;162(1-2):148-61
references.pmid: 21925552
references.citation: Sci Transl Med. 2012 Jan 4;4(115):115ra2
references.pmid: 22218691
references.citation: Sci Transl Med. 2012 Oct 31;4(158):158ra146
references.pmid: 23115355
references.citation: Eur J Immunol. 2005 Sep;35(9):2617-26
references.pmid: 16114109
references.citation: J Med Virol. 2010 Mar;82(3):407-14
references.pmid: 20087930
references.citation: Lancet. 2011 Mar 5;377(9768):849-62
references.pmid: 21084112
references.citation: J Infect Dis. 2011 Jul 15;204(2):200-8
references.pmid: 21571728
references.citation: J Immunol. 2001 Jul 1;167(1):181-7
references.pmid: 11418647
references.citation: Expert Rev Vaccines. 2011 Sep;10(9):1307-19
references.pmid: 21919620
references.citation: Mol Ther. 2008 Jan;16(1):154-62
references.pmid: 17848961
references.citation: PLoS One. 2008;3(10):e3548
references.pmid: 18958172
references.citation: J Virol. 2010 Oct;84(19):9810-6
references.pmid: 20686023
references.citation: Nat Protoc. 2009;4(4):592-604
references.pmid: 19373230
references.citation: Blood. 2004 Jul 15;104(2):487-94
references.pmid: 15059848
references.citation: Gene Ther. 2009 Mar;16(3):367-75
references.pmid: 19129860
references.citation: J Infect Dis. 2007 Nov 15;196 Suppl 2:S357-63
references.pmid: 17940971
references.citation: Curr Opin Immunol. 2011 Jun;23(3):377-82
references.pmid: 21514130
references.citation: Nat Med. 2011 Aug 21;17(9):1128-31
references.pmid: 21857654
references.citation: Nat Med. 2007 Jul;13(7):843-50
references.pmid: 17558415
references.citation: J Comp Pathol. 2001 Nov;125(4):243-53
references.pmid: 11798241
references.citation: Sci Transl Med. 2012 Jun 13;4(138):138ra81
references.pmid: 22700957
references.citation: J Virol. 2004 Mar;78(6):2666-73
references.pmid: 14990686
references.citation: PLoS One. 2012;7(4):e34884
references.pmid: 22514686
references.citation: J Virol. 2007 Apr;81(7):3414-27
references.pmid: 17229693
references.citation: J Infect Dis. 1998 Sep;178(3):651-61
references.pmid: 9728532
references.citation: Front Immunol. 2011 Sep 27;2:39
references.pmid: 22566829
references.citation: Gene Ther. 2005 Mar;12(5):427-36
references.pmid: 15647774
references.citation: Clin Diagn Lab Immunol. 2004 Mar;11(2):351-7
references.pmid: 15013987
references.citation: Clin Vaccine Immunol. 2012 Jan;19(1):84-95
references.pmid: 22089246
references.citation: Cold Spring Harb Perspect Biol. 2013 Mar 01;5(3):a013003
references.pmid: 23388625
references.citation: J Wildl Dis. 2012 Jan;48(1):157-67
references.pmid: 22247384
references.citation: J Immunol. 2010 Aug 1;185(3):1513-21
references.pmid: 20610651
references.citation: PLoS Negl Trop Dis. 2012;6(3):e1575
references.pmid: 22448295
references.citation: Mol Pharm. 2012 Jan 1;9(1):156-67
references.pmid: 22149096
references.citation: J Infect Dis. 1999 Feb;179 Suppl 1:S203-17
references.pmid: 9988186
references.citation: Virology. 2010 Apr 10;399(2):290-8
references.pmid: 20129638
references.citation: Curr Gene Ther. 2011 Aug;11(4):241-58
references.pmid: 21453281
references.citation: J Virol. 2012 Sep;86(18):9590-8
references.pmid: 22787208
references.citation: PLoS One. 2012;7(3):e33428
references.pmid: 22432020